Former Bristol Myers Squibb, Goldman Sachs, and Barclays executive brings deep expertise in corporate strategy, partnership development, public and private financial markets, and management as the organization evolves its leadership and investment strategy
Appointment signals plans to capitalize on previous success and maximize impact by expanding equity investments and partnerships with venture capital, large biopharma, and key foundations with a proven team leader and dealmaker
, /PRNewswire/ — The T1D Fund, an impact investment fund with a focus on accelerating life-changing solutions to treat, prevent, and cure type 1 diabetes (T1D), today announced it appointed Elizabeth Milyas Chief Executive Officer. With more than 30 years of pharma, healthcare investment banking, and strategic leadership experience, Mily will leverage her mission-driven commitment to spearheading the next chapter of the Fund, guiding continued deployment of resources and supporting a comprehensive approach to curing type 1 diabetes. Under her leadership, the T1D Fund expects to …